Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

aboratorios Almirall, S.A.,0 个研究点目标入组 0 人开始时间: 2009年11月18日最近更新: 2023年9月4日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 40 至 90（—）

入选标准

•Males and non-pregnant, non-lactating females aged = 40.
•Patients with a clinical diagnosis of stable moderate to severe COPD, according to the GOLD guidelines: (http://www.goldcopd.com) and stable airway obstruction. Post-salbutamol FEV1/FVC < 70% at Screening Visit (Visit 1) (i.e., 100xpost-salbutamol FEV1/FVC <70%).
•Patients whose FEV1 at Screening Visit measured between 10-15 min post inhalation of 400 µg of salbutamol is = 30% <80% of the predicted normal value (i.e., 100xobserved post-salbutamol FEV1/ predicted FEV1 <80%). Predicted normal values to be used for calculation purposes are to be based on European Community for Steel and Coal predicted values (Quanjer et al. 1993).
•Patients must be able to perform repeatible pulmonary function testing for FEV1 according to ATS/ERS 2005 criteria at Screening Visit (Visit 1).
•Current or former cigarette smokers with a smoking history of at least 10 packs-year. Pack-years are calculated by dividing the number of cigarettes smoked per day by 20 (the number of cigarettes in a pack) and multiplying this figure by the number of years a person has smoked. For example, a person who smokes 40 cigarettes a day and has smoked for 10 years would have a 20 pack-year smoking history (40 cigarettes per day ÷ 20 cigarettes per pack = 2; 2 x 10 years of smoking = 20 pack-year history). Patients smoking other tobacco types will not be allowed, unless they meet the cigarette criterion as well.
•Female patients at least 1 year post-menopausal, surgically sterile (defined as having a hysterectomy or tubal ligation), or practicing a medically acceptable method of contraception. Women of childbearing potential must have a negative pregnancy test at Screening (Visit 1) and be using either double-barrier contraception or a barrier method plus a spermicidal agent.
•Patients who understand the study procedures and are willing to participate in the study as indicated by signing the informed consent.

排除标准

•History or current diagnosis of asthma.
•Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the six weeks before Screening Visit (Visit 1). Patients who develop a respiratory tract infection or exacerbation during the run-in period will be discontinued from the trial before randomisation.
•Patients who have been hospitalised for an acute COPD exacerbation within 3 months prior to Screening Visit.
•Clinically significant respiratory conditions
•Use of long-term oxygen therapy (= 15 hours/day).
•Body Mass Index (BMI) = 40.
•Patients who have participated in an acute pulmonary rehabilitation program within the previous 6 months (NOTE: Patients on a stable pulmonary rehabilitation exercise regimen for at least 6 weeks are not excluded).
•Clinically significant cardiovascular conditions
•Patients with non-controlled history of infection with human immunodeficiency virus (HIV) and/or active hepatitis.
•Patients who have a resting systolic blood pressure = 200 mm Hg, a resting diastolic blood pressure = 120 mm Hg, or a resting heart rate = 105 bpm at Screening Visit (Visit 1) or Visit 2 (pre-randomization).
•QTc [calculated according to Bazett’s formulae (QTc=QT/RR1/2), as indicated in the paper tracing generated by the equipment used to record the ECGs] above 470 milliseconds in the ECG performed at Screening Visit (Visit 1).
•Patients with clinically relevant abnormalities in the results of the clinical laboratory tests, in ECG parameters other than QTc, or in the physical examination at the screening evaluation (Visit 1), if the abnormality defines a disease state listed as an exclusion criteria, except for those related to COPD.
•Patients with a history (within the previous 5 years) of drug and/or alcohol abuse that may prevent compliance with trial activities.
•Patients with any other serious or uncontrolled physical or mental dysfunction that, as judged by the investigator, could place the patient at higher risk derived from his/her participation in the study, could confound the results of the study or is likely to prevent the patient from complying with the requirements of the study or completing the study.
•Patients with a history of hypersensitivity reaction to inhaled anticholinergics, sympathomimetic amines, or inhaled medication or any component

研究者

发起方

aboratorios Almirall, S.A.,

相似试验

进行中（未招募）

1 期

Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD)Moderate to severe chronic obstructive pulmonary disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary disease

EUCTR2009-011600-27-FRaboratorios Almirall, S.A.

进行中（未招募）

不适用

Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD)

EUCTR2009-011600-27-DEaboratorios Almirall, S.A.810

进行中（未招募）

不适用

EUCTR2009-011600-27-HUaboratorios Almirall, S.A.810

进行中（未招募）

不适用

EUCTR2009-011600-27-CZaboratorios Almirall, S.A.810

进行中（未招募）

不适用

EUCTR2009-011600-27-GBaboratorios Almirall, S.A.810